- Display 45 Products per page
Published: April 7, 2020 | Price: $750.00 – $1,000.00
For years, Kalorama Information has covered the fields of molecular diagnostics, immunoassays, vaccines and telehealth. These all find themselves both sought-after and challenged during the current COVID-19 crisis. This report provides trending developments, company announcements and analysis from the Kalorama analysis team on the fast-breaking events in the COVID-19 epidemic. Particular sections address the most important market changes: Molecular Diagnostics: It's important to note that the entire molecular testing concept originated in the midst of a crisis, at that time...Published: March 27, 2018 | Price: $0.00
This brief White Paper lists over one hundred companies that are involved in drug discovery in one form or another. A company website and address is provided for each company. The White Paper does not detail companies or discuss the CRO marketplace - for this purpose, please consult our recent report, Outsourcing in Drug Discovery, 8th Edition.Published: July 27, 2016 | Price: $796.00 – $1,592.00
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 analyzes the leading concerns in the pharmaceutical industry, including the late-term pipeline of major competitors. This report provides long-term company sales forecasts based recent market conditions. For each company covered, the report includes late stage product pipeline; late stage product pipeline by therapeutic area, comparing 2009, 2011, 2013 and 2015; total company revenue and total R&D spending, 2011-2015;...Published: April 7, 2014 | Price: $500.00 – $1,000.00
Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 Kalorama Information's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions. For each company, the report provides: Revenues R&D Spending Geographic Breakout of Revenues Performance of Specific Products Performance by Drug Category Late-Stage Pipeline Projections of Revenues to 2023 In addition...Published: December 4, 2012 | Price: $500.00 – $1,000.00
This Kalorama Information report – The Next Wave in Cancer Treatment--Kinase Inhibitors - is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including: Breast Colorectal Head/Neck Kidney Leukemia Liver Lung Melanoma Ovarian Pancreatic Prostate Stomach The report covers both currently marketed and late stage development kinase inhibitors for cancer treatment. Revenues for this market segment were generated using dollar...Published: December 1, 2011 | Price: $150.00 – $300.00
Kalorama Information reports on a wide range of topics related to healthcare industry markets in the United States. This report, The Kalorama U.S.Pharmaceutical, Medical Device, Diagnostics Markets provides a broad look at the healthcare system and a summary of the market for the healthcare industry in the United States. The report discusses a range of topics impacting the industry: Healthcare Reform - What Impact Will Be Had on Each Healthcare Industry? How Will Physicians, Patients, Payors, and the Uninsured Be...Published: November 1, 2011 | Price: $150.00 – $300.00
Arthritis is one of the most common human ailments worldwide. Arthritis is a complex family of musculoskeletal disorders with many causes that are not fully understood. The most crippling of the arthritis family is rheumatoid arthritis, which is an autoimmune disease. Successful treatment of arthritis has resulted from a growing array of therapies available to physicians. While these pharmaceutical products are still used regularly, new disease-modifying therapies have produced the most impressive results in treating more severe types of arthritis....Published: July 1, 2011 | Price: $150.00 – $300.00
As researchers work to improve drug properties through drug design and molecular modeling, the line between drug delivery and drug substance will become more and more elusive in the near future, as shown in the analysis in this report. Consequently, in the next decade, drug delivery technologies will be a focal point of competition within the pharmaceutical industry and the needle-free drug delivery market will continue to grow rapidly. This Kalorama Information report, Needle-Free Drug Delivery: The Market for Alternatives...Published: July 1, 2011 | Price: $150.00 – $225.00
The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high. The global market for vaccines experienced strong growth through 2010 and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions. Kalorama Information has been closely following vaccine markets and has instituted a yearly market research report schedule since 2003 in order to keep up with fast-moving...Published: April 1, 2011 | Price: $150.00 – $300.00
This Kalorama Information report - The World Market for Clinical Nutrition Products - focuses on three primary segments of essential medical nutrition: Infant Nutrition: (Milk-based, Soy-based, Special Needs such as Chronic Reflux or Gastrointestinal Discomfort) Enteral Nutrition (Standard and Fiber-containing Elemental and Semi-elemental, Specialized for Chronically Ill Patients) Parenteral Nutrition For each category, the report provides revenue data and forecasts for the most important segmentations. The report includes incidence of conditions which often require enteral or parenteral feeding, birth rates,...Published: March 25, 2011 | Price: $150.00 – $300.00
The Asian vaccine market is relatively small compared to its population, yet it is growing, and pharmaceutical manufacturers increasingly will look to boost sales from these emerging vaccine markets. The population of nearly 4 billion people throughout Asia accounts for more than half of the global population, yet currently it is Western markets which lead vaccine sales. This hasn't stopped companies from investing in Asian vaccine markets. The graying of the population in Asia and the growth in some regions...Published: February 1, 2011 | Price: $150.00 – $300.00
While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over-the-counter drugs are widely anticipated to grow as consumers seek cheaper alternatives. Manufacturers are expected to switch prescription drugs to over-the-counter status where possible. In the early part of the last decade there was a decline in Rx-to-OTC switches; since 2006, however, there has been a number of uses of this tactic to extend the revenue of pharmaceutical products. In Kalorama Information's Market for...Published: May 1, 2010 | Price: $500.00 – $2,400.00
The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to demonstrate that working with governments of the US and countries around the world, they could manufacture and distribute a vaccine for the virus strain that may have had an impact in reducing cases and deaths. Who were the companies that performed best in this market? How did goverment contracts play out? Most importantly, what are lessons for future pandemic and...Published: November 1, 2008 | Price: $195.00 – $995.00
Often what separates successful marketing from bad is good competitive intelligence. This is true in life sciences as much as other industries. Many companies approach CI in a way that is unplanned, indirect and harmful to their business. But how does one know if they are conducting their company's CI in the best way? If you are trying to determine how to use competitive intelligence better, if you are attempting to judge your efforts compared to companies that have been...Published: November 1, 2008 | Price: $995.00 – $1,990.00
At present the Middle East region constitutes as small percent of global pharmaceutical sales. However, ever-increasing populations and governmental healthcare reforms are likely to increase demand. These markets will be essential for pharmaceuticals companies exploring new opportunities for growth. Developing regions will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. This Kalorama Information report, Pharmaceutical Markets in the Middle East (Opportunities, Key Players, Trends) takes a thorough look at the...Published: July 1, 2008 | Price: $500.00 – $7,000.00
Pharmaceutical markets in Brazil, Russia, India and China rank among the top twenty markets in the world with the potential to move up in ranking rather quickly. (China’s pharmaceutical market, for instance, is expected to show double-digit growth over the next five years.) Developing regions and petro-rich nations will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. Kalorama's Pharmaceutical Markets in Brazil, Russia, India and China (BRIC nations) takes a...Published: May 1, 2008 | Price: $995.00 – $6,400.00
Over-the-counter (OTC) drugs are well situated to capitalize on worldwide economic conditions. Customers in the US and in the world under time constraints and tight budgets prefer OTC and are opting to self-medicate where possible. Developing and petro-rich nations are pushing world demand for pharmaceuticals. Pharmacists are favoring OTCs, and are a driving force behind a new class of 'behind the counter' (BTC) drugs. The aging of the population and an increase in medical conditions generally continues to bode well...Published: April 1, 2008 | Price: $500.00 – $3,990.00
Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life. Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the US market for prescription drugs likely to switch in the...Published: April 1, 2008 | Price: $995.00 – $7,000.00
In one sense, the opportunity for follow-on proteins is as good as ever. Some of the biggest-selling biologics developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection or are set to lose patent protection in the US in 2007 and beyond. But there are also regulatory challenges to marketing follow-on biologics in the U.S. that companies will need to navigate to prosper. In this report, Biogenerics:...Published: April 1, 2008 | Price: $995.00 – $7,990.00
Generics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics. Kalorama Information's World Market...Published: April 1, 2008 | Price: $995.00 – $8,200.00
Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2007 and 2008. Since Kalorama Information last updated Kalorama Information's The World Market for Vaccines in the first quarter of last year, new products and better than expected profits have transformed the vaccine marketplace. Approvals that have been granted for products such as RotaTeq, Pentacel, Adacel and Zostavax and FluMist are now impacting the market. The launch and execution of the first...Published: March 1, 2008 | Price: $995.00 – $3,990.00
Pharmaceutical manufacturers are utilizing new RIFD technologies to deal with multiple challenges they face in the manufacturing process. This Kalorama Information report discussions the solutions available, and covers the opportunities available to technology companies to provide services to this sector. Full coverage of the market for RFID technologies in pharmaceutical manufacturing operations is provided, including. Explanation of RFID Technologies Cost Savings from Implementation Total Market for RFID Technologies in Pharma Manufacturing Market Forecasts Major Companies Involved in RFID and...Published: February 1, 2008 | Price: $895.00 – $6,990.00
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment. Kalorama Information's Congestive Heart Failure, Major...Published: February 1, 2008 | Price: $995.00 – $7,990.00
Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to the pharmaceuticals, aid the innovations in the drug development and help improve patent life as well. Excipients make the products more functional at a lower cost, a benefit much desired by the pharmaceutical industry that is inundated with pressures to reduce costs. All in all, excipients...Published: January 1, 2008 | Price: $995.00 – $7,000.00
Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. Kalorama's Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for...Published: January 1, 2008 | Price: $995.00 – $7,990.00
Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. Pediatric Drugs, the...Published: December 1, 2007 | Price: $995.00 – $7,990.00
Kalorama's 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products and the pipeline in this comprehensive market study. The following market segments are covered: Cardiac Glycosides and Positive Inotropic Agents Antihypertensive Agents (ACE Inhibitors, Angiotensin...Published: October 1, 2007 | Price: $995.00 – $5,000.00
In five years, Kalorama Information believes that given the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will...Published: October 1, 2007 | Price: $995.00 – $1,990.00
It can be said that pharmaceutical companies face a 'new era.' in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there is very little margin for error in the pricing decision. Drug pricing is one of the key levers that determine the profitability of a drug...Published: August 1, 2007 | Price: $995.00 – $1,990.00
The unrecognized importance, danger and costs of hepatitis in the 21st century cannot be understated or underestimated. The impact of the disease on world society is highly significant and now presenting a major crisis in public health circles. In his exhaustive analysis of the potential diagnosis, screening and therapeutic markets for hepatitis, Ken Krul, PhD. advises companies to think on a global basis. In this study, Global Hepatitis Strategies Krul examines the potential market, epidemiology (hepatitis patient trends) and technology...Published: June 1, 2007 | Price: $500.00 – $5,990.00
Multiple sclerosis (MS) is a chronic demyelinating CNS disease that causes significant disability in young adults and others. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life. Kalorama Information's: Multiple Sclerosis Treatments: World Market Outlook to 2011 is one of the few publications to take a detailed look at multiple sclerosis treatment market worldwide, as well as treatments that...Published: June 1, 2007 | Price: $995.00 – $1,990.00
The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles. As illustrated by Kenneth G. Krul, Phd., in Kalorama Information's Global Tuberculosis Strategies, there are abundant opportunities for diagnostic and pharmaceutical companies in combating the global tuberculosis threat. As the author details, there are primarily three focal...Published: January 1, 2007 | Price: $995.00 – $7,000.00
The market for psychotherapeutics drugs is about to change dramatically -- and serious pharmaceutical market watchers will want to be prepared. Kalorama’s Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs: World Market is the most exhaustive guide available to this booming market and the direction it is headed in the next four years. Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a determined amount of time causing distress or emotional/physical impairment. Depression, anxiety, psychosis, ADHD and nicotine and...Published: October 1, 2006 | Price: $995.00 – $7,000.00
The orthopedic drug market is a highly competitive market and, in some areas, the competitive environment is being shaped by increasing levels of generic competition. Several large pharmaceutical companies compete in the orthopedic drug market, including Abbott, Eli Lilly, GlaxoSmithKline, Merck, Novartis, and Pfizer among others, and several other suppliers, such as Serono, NovoNordisk, Amgen, and Genentech are developing or offering products in more niche market areas. For the purposes of this study, the world market for orthopedic drugs has...Published: July 1, 2006 | Price: $995.00 – $7,000.00
This report provides and in-depth analysis of the market for prescription drugs used in the treatment of gastrointestinal (GI) disorders, such as nausea and vomiting, heartburn, gastro-esophageal reflux disease (GERD), ulcer, cancers of the GI tract (colorectal, esophageal, and gastric), Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS), diverticular disease, constipation, celiac disease, short bowel syndrome, diarrhea, intestinal obstruction, and digestive enzyme disorders. For each major segment, the analysis provides an overview of the diseases including epidemiology, a detailed description...Published: June 1, 2006 | Price: $995.00 – $5,990.00
This report focuses on the specific needs and market applications of the critical care pharmaceuticals market, the options presented by the market, the factors associated with strategic market development, and prospects for the future. The major indications for critical care are discussed as well as the range of pharmaceutical products used in the critical care environment. The strategic market characteristics of the critical care pharmaceuticals market are also discussed. The trends —- cost-containment programs, restricted formulary acceptance, clinical pharmacy, and...Published: June 1, 2006 | Price: $995.00 – $7,000.00
Despite troublesome safety problems with past entrants into this market, the veritable epidemic of overweight and obesity continues to make this sector an extremely attractive target for pharmaceutical developers. This new title provides a considered view of the market for medical interventions in the battle against obesity, including U.S. and worldwide market size and growth forecasts, competitive market share and extensive pharmaceutical pipeline information. The report discusses both prescription and OTC drug markets and surgical interventions. Market size and growth...Published: January 1, 2006 | Price: $995.00 – $5,990.00
With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products. As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will impose unprecedented demands on the industry’s biomanufacturing capacity. Whether or not this will create a biomanufacturing bottleneck is a hotly debated issue in the industry....Published: August 1, 2005 | Price: $795.00 – $1,990.00
Neurological disease that impacts the sensory pathway can produce severe chronic pain, also known as neuropathic pain. This usually is unrelated to any peripheral tissue injury. This occurs with disorders of the central nervous system (CNS), such as stroke and multiple sclerosis, or with conditions associated with peripheral nerve damage, such as mechanical injury, diabetic neuropathy or herpes zoster infection. On form of neuropathic pain that is just now gaining recognistino is complex regional pain syndrome (CRPS), also known as...Published: April 1, 2005 | Price: $995.00 – $1,990.00
Schizophrenia is a life long affliction. There is no permanent cure for this illness. However, numerous drugs have made the effective management of the disease a reality. This briefing examines both corrent and emerging therapeutic approaches for the management of schizophrenia. It provides an analysis of the current and future markets for these agents, including forecasts to 2009 segmented by geographic region and by type of drug and likely market scenarios for new agents not yet available. The briefing discusses...Published: January 15, 2005 | Price: $995.00 – $1,990.00
Despite the traditional notion that nothing therapeutic can be accomplished for the 1.5 million Americans with autism and the 2 million more throughout the world, there are pharmacologic approaches to the disease that are providing some help for patients and garnering revenues for drug companies. This Market Briefing reviews the market for drugs used in the treatment of autism and related disorers, including Antidepressants, Anti-Anxiety drugs, Anti-psychotics, Anti-convulsants, and CNS stimulants for ADHD-related symptoms, forecasting revenues through 2009 gloabally and...Published: October 1, 2004 | Price: $895.00 – $1,790.00
There is a pressing need for new anticoagulant therapeutics in human medicine. To meet this need, developers are reformulating traditional cornerstone therapeutics such as heparin and looking to new classes such as DTIs to prevent stroke and myocardial infarction and treat deep vein thrombosis and a host of other emerging indications. This briefing analyzes the potential world medical markets for new anticoagulant therapies. Revenue projections through 2010 are made for four geographic regions and for two potentially blockbuster products. This...Published: August 1, 2004 | Price: $895.00 – $1,790.00
After years of neglect, concerns over pain, how it is assessed and managed on a patient-by-patient basis have captured the attention of health care professionals and the public. There are a variety of issues that have acted to draw this attention, including the high prevalence of pain, continuing evidence that pain is undertreated and a growing awareness of the negative consequences of poor pain management. Infusion pumps were first introduced in the 1960s. These devices ushered in a whole new...Published: March 1, 2004 | Price: $795.00 – $1,590.00
The hard-fought battle over Medicare's prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all the facts. This market briefing from Kalorama describes and assesses the provisions of the "Medicare Prescription Drug, Improvement and Modernization Act of 2003" and predicts...Published: November 7, 2003 | Price: $746.00 – $1,492.00
Over the past three years, Kalorama Information's analysts have studied drug delivery markets from several angles. In 2001 and 2002, we published a 5-volume series on drug delivery technology, each volume devoted to a route of administration: Volume I: Oral Drug Delivery Volume II: Injectable and Implantable Drug Delivery Volume III: Pulmonary Drug Delivery Volume IV: Transdermal and Transmucousal Drug Delivery Volume V: Advanced Drug Delivery This series segmented the market by technology and included an innovative analysis that estimated...